SAN DIEGO, Feb. 20, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTC BB:INNV) today announced that it will exhibit Zestra®, its topical over the counter ("OTC") product for female sexual arousal and desire at the 2014 Annual International Society for the Study of Women's Sexual Health Meeting in San Diego from February 20-22, 2014.
Zestra® is an OTC natural product clinically-proven in two U.S. double blind placebo controlled clinical trials in 276 women to increase arousal, desire and reduce pain during sexual intercourse. The Company currently sells Zestra® in the U.S .and Canada and has sold millions of doses since its launch. Zestra® has a very favorable safety profile and works within 4-5 minutes of application.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in the OTC male and female sexual dysfunction products. The Company generates revenues from its lead products Zestra® for female arousal, and EjectDelay™ for premature ejaculation, and has a total of four marketed products in this space including the above products and CIRCUMSerum™ ex US and Zestra® Glide.
For more information, go to www.innovuspharma.com.
INNOVUS PHARMA'S FORWARD-LOOKING Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products, to successfully commercialize such products as Zestra®, and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
CONTACT: Innovus Pharma Contact: Kevin Holmes Chesapeake Group email@example.com T: 410-825-3930Source:Innovus Pharmaceuticals, Inc.